Trevi Therapeutics (TRVI) to Post Quarterly Earnings on Thursday

Posted by Brian Himes on Aug 5th, 2026

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) will likely be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Trevi Therapeutics to announce earnings of ($0.1095) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). On average, analysts expect Trevi Therapeutics to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Trevi Therapeutics Trading Up 4.7%

NASDAQ TRVI opened at $18.75 on Wednesday. Trevi Therapeutics has a 12 month low of $6.55 and a 12 month high of $20.22. The stock has a market cap of $2.66 billion, a P/E ratio of -58.59 and a beta of 1.03. The stock’s fifty day moving average price is $16.72 and its 200-day moving average price is $13.86.

Institutional Investors Weigh In On Trevi Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TRVI. Rubric Capital Management LP boosted its stake in shares of Trevi Therapeutics by 88.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock worth $46,669,000 after buying an additional 3,993,325 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Trevi Therapeutics by 9.6% in the third quarter. Vanguard Group Inc. now owns 5,826,986 shares of the company’s stock worth $53,317,000 after buying an additional 510,295 shares during the last quarter. Viking Global Investors LP grew its position in Trevi Therapeutics by 232.4% during the third quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock valued at $46,929,000 after buying an additional 3,585,875 shares during the period. Vivo Capital LLC grew its position in Trevi Therapeutics by 13.5% during the third quarter. Vivo Capital LLC now owns 5,094,668 shares of the company’s stock valued at $46,616,000 after buying an additional 606,765 shares during the period. Finally, Marshall Wace LLP increased its holdings in Trevi Therapeutics by 95.4% during the third quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock valued at $44,302,000 after buying an additional 2,363,835 shares during the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TRVI. BMO Capital Markets started coverage on shares of Trevi Therapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $36.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, May 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $19.00 target price on shares of Trevi Therapeutics in a report on Friday, April 17th. Wall Street Zen downgraded shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $24.91.

View Our Latest Analysis on Trevi Therapeutics

About Trevi Therapeutics

(Get Free Report)

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.